"Prognostic Evaluation in Patients with Acute Myeloid Leukemia, From Diagnosis to Treatment: A Single- Center Experience"

Abstract

A total of 124 patients followed-up with the diagnosis of AML with known clinical, laboratory, and flow cytometry results in 2016-2019 were retrospectively examined. Sixty nine of the cases (55.6%) were male and 55 (44.3%) were female. The average age at the time of diagnosis was 53.44±30.3 years old. The median follow-up time was 856 (143-1276) days. It was found that presences of >60 age, male gender, non-APL AML, bcr-abl positivity, recurrence, and requirement of re-induction were related to lower survival. The time between diagnosis and therapy was longer at the patient group unresponsive to therapy. The median follow-up duration was 856 (143-1276) days and 74 of our patients (59.6%) are alive. We detected in our study that the flow cytometry results and the short time to initiation of therapy possibly affect the response to therapy. The immunophenotype and genetic results may be combined to have an idea of prognosis and may affect therapy regimen preference.